Abbott Japan made the prescription medication, which is indicated for chronic constipation caused not due to organic diseases, available to physicians in Japan.
Sucampo chairman, chief executive officer and chief scientific officer Ryuji Ueno said millions of patients in Japan have been suffering from chronic constipation for many years.
"Until the approval of AMITIZA, there had been no new chemical entity developed for chronic constipation in Japan in 32 years," Ueno added.
"Sucampo and Abbott are honored to bring AMITIZA to the Japanese market, and we look forward to the positive impact we hope this medicine will have for patients who need it."
The chloride channel activator Amitiza owns a different mode of action to re-establish mucosal barrier function in the patients.